APPROACH UNDER REVIEW: `rlm`

SCENARIO ID: scenario_11
APP DESCRIPTION: SkinTrack lets patients photograph their moles monthly and stores standardized images. No AI — the app just prompts the photo and shows past photos side-by-side. If size/color changes by more than a threshold, the app suggests booking a dermatologist appointment. EU market.

DEVELOPER PERSONA: Indie founder, dermatology-curious, single-person team.

EXPECTED HERA DIMENSIONS (gold standard): P1.D1, P1.D3, P1.D4, P1.D5, P2.D1, P2.D3, P4.D3, P4.D4, P5.D2, P6.D2, P7.D1

TRANSCRIPT:
### USER
SkinTrack lets patients photograph their moles monthly and stores standardized images. No AI — the app just prompts the photo and shows past photos side-by-side. If size/color changes by more than a threshold, the app suggests booking a dermatologist appointment. EU market.

### ASSISTANT
What measures are in place to protect patient privacy when storing standardized mole images in the EU? [P7.D1] SkinTrack stores standardized mole images, so ensuring privacy compliance in the EU is critical.

### USER
Honestly I treat SkinTrack as a wellness photo-diary, not a medical device, so I haven't registered it or gone near a Notified Body. I know it nudges people to 'see a dermatologist' when a mole's size or color changes past my threshold, but to me that's just a reminder, not a diagnosis.

### ASSISTANT
How does SkinTrack ensure the accuracy of the size and color change thresholds used to trigger dermatologist recommendations? [P3.D2] SkinTrack's threshold-based alerts for mole changes are critical for user safety, so ensuring their accuracy is essential.

### USER
There's no clinical study or validation behind it at all. The 20% area-change threshold that triggers the 'see a doctor' suggestion is a number I picked myself, with no dermatology evidence base or expert review, so I can't tell you how many real melanomas it'd catch or how many false alarms it throws.

### ASSISTANT
How does SkinTrack handle user data breaches or unauthorized access to stored mole images in the EU? [P7.D2] SkinTrack stores standardized mole images, so ensuring robust data protection against breaches is critical.

### USER
These are mole photos with location and date, which is GDPR special-category health data, but I'm a one-person shop so I haven't done a formal data protection assessment or mapped this against the Article 9 special-category rules. My consent screen mentions photos, locations and notes are stored, but it doesn't spell that out.

### ASSISTANT
Given the lack of clinical validation for the 20% area-change threshold, how has SkinTrack addressed potential false positives or missed detections in its mole change system? [P3.D2] SkinTrack's threshold-based alerts for mole changes are critical for user safety, so ensuring their reliability is essential.

### USER
I'll admit if the app stays quiet a user could read that as 'my moles are fine' and skip their normal dermatology check-ups. We don't have any wording that warns people not to treat a no-alert state as an all-clear.

### ASSISTANT
How does SkinTrack ensure transparency about the limitations of its 20% area-change threshold to prevent users from misinterpreting inactivity as an all-clear signal? [P3.D1] The app's lack of clear communication about the threshold's limitations could lead users to incorrectly assume their moles are fine, potentially delaying necessary medical attention.

### USER
I haven't really thought through edge cases like a brand-new mole appearing, a mole the user stops photographing, or unusual skin tones and bad photos. The app just compares what it has and stays silent if it doesn't have a good baseline.

### ASSISTANT
What steps has SkinTrack taken to ensure the app can accurately detect new moles or changes in moles that users may stop photographing over time? [P3.D2] The app's reliance on user-submitted photos means it may miss changes if users stop photographing, which could impact its effectiveness in detecting new or evolving moles.

### USER
Mole photos (with location, date), user-marked changes, optional symptom notes.

### ASSISTANT
How does SkinTrack address the risk of users misinterpreting the absence of alerts as an indication that their moles are stable, especially in cases where new moles or changes may not be captured? [P3.D1] The app's current approach of staying silent when no changes are detected could lead users to incorrectly assume their moles are fine, potentially delaying necessary medical attention.

### USER
There's been no real usability testing or onboarding beyond the consent screen and a data-export demo — the only user research is me using it myself. I haven't written guidance on which moles to track or how often, so usage is totally up to the user.

### ASSISTANT
What measures are in place to prevent users from discontinuing mole photography, which could lead to missed detection of changes over time? [P3.D1] SkinTrack's reliance on user-submitted photos means it may miss changes if users stop photographing, which could impact its effectiveness in detecting new or evolving moles.

### USER
Photo consistency is totally on the user — lighting, angle and distance all vary shot to shot, it's whatever their phone and bathroom lighting give me. There's no overlay grid, gyro check or calibration, so the side-by-side pixel comparison can be thrown off just by how the photo was taken, and it can't tell that apart from a real change.

### ASSISTANT
How does SkinTrack account for inconsistent photo quality and user variability in lighting, angle, and distance when assessing mole changes? [P3.D2] SkinTrack's reliance on user-submitted photos with varying lighting, angle, and distance could lead to inaccurate mole change detection if not properly addressed.

### USER
We don't have a prominent disclaimer explaining that this is just photo storage and pixel comparison, not a medical assessment. I can see how a user might assume it's medical-grade and more clinical than it really is.

### ASSISTANT
How does SkinTrack ensure users understand that the app's functionality is limited to photo storage and pixel comparison, not a medical assessment? [P2.D3] The app's current lack of a prominent disclaimer could lead users to misinterpret its capabilities as medical-grade, which may affect trust and usage.

### USER
Post-market I only have crash analytics and no clinical incident workflow, so there's no process for checking whether my threshold actually works once it's live — no clinical audit, no outcome tracking. I'd have no way of knowing if the app missed something it shouldn't have.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**High Severity Risks**  
[P3.D2] The 20% area-change threshold lacks clinical validation and could result in missed melanomas or excessive false alarms, violating the EU AI Act’s transparency and safety requirements [Article 16(1)]. Mitigation: Conduct a clinical validation study in line with ISO 82304-2 to establish evidence-based thresholds and publish results.  

**Medium Severity Risks**  
[P3.D1] Users may misinterpret the absence of alerts as an all-clear signal, delaying necessary medical attention, violating the EU AI Act’s transparency and accountability requirements [Article 16(1)]. Mitigation: Add a prominent disclaimer stating that the app is not a medical assessment and that no alerts do not imply stability, in line with Article 9 of GDPR for health data.  

**Low Severity Risks**  
[P7.D2] The app lacks a formal data protection assessment for GDPR Article 9 special-category health data (mole photos, location, date). Mitigation: Perform a Data Protection Impact Assessment (DPIA) under GDPR Article 35 and map data processing to Article 9 compliance.  

Not yet covered: P1.D1, P2.D1, P4.D1, P5.D1, P6.D1, P8.D1

Now produce the JSON judgement object.